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Abstract
Background: Drugs for dementia have been available in England since 1997. Since their launch, there have been
several changes to national guidelines and initiatives that may have influenced prescribing. These include changes
in National Institute for Health and Care Excellence (NICE) guidance, several government dementia strategies, the
addition of dementia to the Quality and Outcomes Framework (QOF), and the expiry of drug patents. Despite this,
there has been little research into the effect of these events on prescribing. This paper examines prescribing trends
in England using data from the U.K. Clinical Practice Research Datalink since the launch of drugs for dementia up
to 1st January 2016.
Methods: We considered the monthly proportion of patients eligible for treatment, with a diagnosis of probable
Alzheimer’s disease, receiving their first prescription for each drug class—namely, acetylcholinesterase (AChE) inhibitors
(donepezil, rivastigmine, galantamine) and N-methyl-D-aspartate (NMDA) receptor antagonists (memantine). Trend
analysis using joinpoint models was then applied to identify up to two trend changes per treatment of interest.
Results: The overall trend was for increasing prescriptions in each drug class over the period in which they were
studied. This was indicated by the average monthly percentage change, which was 6.0% (95% CI, − 6.4 to 19.9; June
1997 to December 2015) for AChE inhibitors and 15.4% (95% CI, − 77.1 to 480.9; January 2003 to December 2015) for
NMDA receptor antagonists. Prescriptions of AChE inhibitors increased at the end of 2012, probably in response to the
patent expiry of these drugs earlier that year. The Prime Minister’s Dementia Challenge launched in May 2012 may also
have contributed to the observed increase. However, neither this strategy nor patent expiry appeared to influence
prescriptions of NMDA receptor antagonists. Instead trend changes in this drug class were driven by NICE guidance
released in 2011 that allowed access to these drugs outside of clinical trials.
Conclusions: Dementia drug prescribing does not always respond to factors such as regulatory guidance,
recommendations, or patent expiry, and when it does, not necessarily in a predictable way. This suggests that
communication with clinicians may need to be improved to use drugs for dementia more cost-effectively.
Keywords: Alzheimer disease, Dementia, Donepezil, Rivastigmine, Galantamine, Memantine, Clinical Practice Research
Datalink, National Institute for Health and Care Excellence, Quality and Outcomes Framework, England
* Correspondence: venexia.walker@bristol.ac.uk
1Bristol Medical School: Population Health Sciences, University of Bristol,
Bristol, UK
2MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Walker et al. Alzheimer's Research & Therapy  (2018) 10:51 
https://doi.org/10.1186/s13195-018-0379-6
Background
There are currently four licensed treatments that pro-
vide symptomatic relief for patients with Alzheimer’s
disease in England—three acetylcholinesterase (AChE)
inhibitors (donepezil, rivastigmine, galantamine) and one
N-methyl-D-aspartate (NMDA) receptor antagonist
(memantine). These drugs are collectively referred to as
drugs for dementia in the British National Formulary,
despite their licensing for Alzheimer’s disease only [1].
Since the first of these drugs became available in 1997,
there have been several changes in national guidelines
for the treatment of Alzheimer’s disease, as well as
several initiatives to encourage better diagnosis and
treatment of the disease. Despite this, there has been lit-
tle research into whether such changes to guidelines and
initiatives have directly influenced clinical practice [2, 3].
We examined how prescription rates in England have
changed since the launch of these drugs up to 1st
January 2016, using data from the U.K. Clinical Practice
Research Datalink (CPRD). We investigated how
prescribing was affected by changes in National Institute
for Health and Care Excellence (NICE) guidance (includ-
ing the 2006 guidance that was subject to legal
challenges), the addition of dementia to the Quality and
Outcomes Framework (QOF), the introduction of ambi-
tious government dementia strategies, and the expiry of
drug patents. The timing of each of these changes,
which may have influenced aspects of drug prescribing
and clinical practice, is discussed further below and
summarized in Table 1.
NICE guidance on the prescribing of drugs for dementia
In the past NICE guidance has used scores from the
Mini Mental State Examination (MMSE), in combin-
ation with other measures, to guide whether a patient
should be prescribed a drug for dementia. The test,
proposed in 1975 by Folstein et al., assesses a patient’s
cognition out of a total possible score of 30, where nor-
mal cognition is considered as a score of 24 or more [4].
The original NICE guidance, issued in 2001, on the use
of drugs to treat Alzheimer’s disease recommended that
the three AChE inhibitors should be used for all patients
scoring 12 or above on the MMSE until the drugs were
deemed no longer effective [5, 6]. In November 2006,
NICE revised their guidance so that the use of AChE
inhibitors was restricted to patients with moderate
Alzheimer’s disease; this was defined as patients scoring
between 10 and 20 points on the MMSE. The 2006
guidance was also the first to consider the use of the
NMDA receptor antagonist memantine, which was rec-
ommended for use only in clinical trials for patients with
moderate to severe disease [7]. This revision of the
guidance was controversial because of the way in which
it assessed cost-effectiveness, which was expected to
restrict access to these drugs, and was ultimately the
subject of a high court challenge by the Alzheimer’s
Society and two drug manufacturers, Eisai and Pfizer
[8–10]. This led to a further revision being made to the
NICE guidance at the end of March 2011, which recom-
mended AChE inhibitors for patients with mild to
moderate Alzheimer’s disease and memantine for
patients with moderate to severe Alzheimer’s disease or
who could not tolerate AChE inhibitors [11]. For the
duration of our present study, treatment had to be
initiated by a specialist and deemed effective as long
as there has been ‘an improvement or no deterior-
ation in MMSE score, together with evidence of
global improvement on the basis of behavioral and/or
functional assessment’ [6].
Inclusion of dementia on the QOF
QOF is a voluntary incentive program, introduced in
2004, to improve services in primary care [12]. Dementia
first appeared in QOF as an ‘indicator’ in September
2007 [13]. There are currently three indicators for de-
mentia included in the framework. The first requires
that the practice establish and maintain a register of
patients diagnosed with dementia, and the other two in-
dicators refer to the ongoing management of the disease
[14]. The inclusion of dementia on the QOF could there-
fore have encouraged a greater focus on the diagnosis
Table 1 Events prior to 1st January 2016 that potentially affected
prescription rates
Event date Event
May 1997 Donepezil first recorded in CPRD
September 1998 Rivastigmine first recorded in CPRD
January 2001 Galantamine first recorded in CPRD
and first NICE guidance released
December 2002 Memantine first recorded in CPRD
November 2006 NICE recommended restricting drug
access
September 2007 QOF revised to include dementia
February 2009 First National Dementia Strategy
launched
March 2011 NICE removed recommendation
restricting drug access
January 2012 Galantamine patent expired
February 2012 Donepezil patent expired
May 2012 Prime Minister’s Dementia
Challenge launched
July 2012 Rivastigmine patent expired
April 2014 Memantine patent expired
February 2015 Prime Minister’s Challenge on
Dementia 2020 launched
CPRD Clinical Practice Research Datalink, NICE National Institute for Health and
Care Excellence, QOF Quality and Outcomes Framework
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and pharmacological management of the disease in par-
ticipating practices.
Government dementia strategies
The first National Dementia Strategy was launched by
the Department of Health in February 2009. The aim of
that strategy was ‘to ensure that significant improve-
ments are made to dementia services across three key
areas: improved awareness, earlier diagnosis and inter-
vention, and a higher quality of care’ [15]. This strategy
was followed in 2012 by the Prime Minister’s Dementia
Challenge, which looked to improve care and research
by 2015, and more recently by the Prime Minister’s
Challenge on Dementia 2020 [16, 17]. The most recent
strategy aims to build on the work of its predecessors to
make England the best place for both dementia care and
research. In general such strategies may help to increase
the awareness of dementia for both the public and
health services [18, 19].
Drug patents
The King’s Fund charity found that the prescription of
generic drugs over their patented alternatives has ‘saved
the NHS around £7.1 billion and allowed more than 490
million more items to be prescribed to patients’ between
1976 and 2013 [20]. AChE inhibitors for the treatment
of Alzheimer’s disease became available generically from
2012, whereas NMDA receptor antagonists became
available generically from 2014 (Table 2) [21]. Therefore,
in recent years the cost of drugs for dementia has de-
creased significantly from previous years. This serves as
a potential factor in rates of prescribing, particularly in
publicly funded health care services such as the NHS in
England.
Methods
Aim
The aim of the study was to examine prescribing trends
in England from the launch of the drugs for dementia
up to 1st January 2016, using data from the CPRD.
Design
This study was a joinpoint analysis of the proportion of
patients eligible for treatment, with a diagnosis of ‘prob-
able Alzheimer’s disease’, receiving their first prescription
for the treatment of interest in each month. We defined
patients as eligible for their first prescription if they had
the diagnosis of interest with no previous prescription
for the treatment of interest. The time period was mea-
sured in units of 1 month because this was the smallest
clinically meaningful measure we could realistically de-
fine. We investigated treatment rates as a proportion of
eligible patients because the underlying rate of diagnosis
of Alzheimer’s disease, as well as non-Alzheimer’s dis-
ease and mixed dementias, has changed over time in the
CPRD (Fig. 1). The joinpoint analysis used in this study
has been developed for incidence rates, so prevalent
drug use, which requires consideration of both incidence
and continued drug use, was not studied.
The four drugs for dementia were separated according
to drug class (i.e., AChE inhibitors and NMDA receptor
antagonists). Exposure date was taken to be the date on
which the first prescription requesting the drug(s) being
considered was recorded. This allowed patients who had
previously been prescribed AChE inhibitors to be in-
cluded in the NMDA receptor antagonist analysis. This
is necessary because NMDA receptor antagonists may
be prescribed alongside AChE inhibitors and are often
given to patients later in the course of their disease, po-
tentially following exposure to AChE inhibitors.
Setting
In this study we used data from the CPRD, an ongoing
U.K.-based primary care database established in 1987.
The data used in this study were obtained as part of a
larger project investigating whether commonly pre-
scribed drugs can be repurposed for the prevention or
treatment of Alzheimer’s and other neurodegenerative
diseases [22]. For this project, we sampled patients older
than 40 years of age with at least 12 consecutive months
of records classified as ‘acceptable’ by the CPRD from an
‘up to standard’ practice. The data were taken from the
March 2016 CPRD GOLD database snapshot, which
covered the period from 1st January 1987 to 29th Febru-
ary 2016, inclusive.
Sample
For this study, we considered the data available from 1st
January 1987 to 31st December 2015, inclusive, from
practices with a last data collection date in 2016; this
Table 2 Patent information for the drugs used for dementia [21]
Generic name Patent name (manufacturer) Drug class Patent expiry
Donepezil Aricept (Eisai / Pfizer) AChE inhibitor January 2012
Rivastigmine Exelon (Novartis) AChE inhibitor February 2012
Galantamine Reminyl (Shire) AChE inhibitor July 2012
Memantine Ebixa (Lundbeck) NMDA receptor antagonist April 2014
AChE Acetylcholinesterase, NMDA N-methyl-D-aspartate
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ensured that all data were complete for the time frame
being considered. We also restricted the data to English
practices. This is because guidelines and initiatives can
differ by nation in the United Kingdom; for example, all
nations are subject to patent expiry, but the National
Dementia Strategy is applicable only to England, with
other nations having their own strategies. Additional file
1 presents a sensitivity analysis investigating the effect of
limiting the study to practices in England. The analysis
concludes that because the majority of the CPRD data is
obtained from English practices and the proportion of
people included in the study is similar for England and
the CPRD as whole, the representativeness of the CPRD
is likely to have been preserved. To be included in the
study, a patient had to have a diagnosis of dementia as
determined by a read or product code (see reference [23]
for code lists). Read and product codes uniquely identify
clinical terms and prescriptions, respectively, in the
CPRD and are recorded by the general practitioner at
the time of the consultation with the date [24]. The val-
idity of codes for dementia diagnoses in the CPRD has
previously been studied and was found to be in concord-
ance with depersonalized written records relating to the
diagnosis [25]. The diagnoses and their definitions as
used in the present study are provided in Table 3. We
used treatment to define diagnosis under the assumption
that treatment implies diagnosis. Diagnosis date was
taken to be the first date on which a code from any of
the lists was recorded. We performed a sensitivity ana-
lysis to test the diagnosis definitions, which is presented
in full in Additional file 2. The analysis considered the
sensitivity and specificity of the diagnoses in the CPRD
dataset using linked data from the Office of National
Statistics (ONS) death registry and the Hospital Episode
Statistics (HES) inpatient dataset. We found there to be
high specificity (HES, 62.9–79.1%; ONS, 57.5–75.1%)
and variable sensitivity (HES, 37.3–71.6%; ONS, 36.0–
80.4%). The high specificity demonstrated in this analysis
reflects our conservative approach when constructing
the code lists. Consequently, we expected a lower sensi-
tivity, and this is in line with what we observed.
Analysis
The analysis of each treatment of interest started on the
first day of the month following the first recorded pre-
scription for that treatment. For example, the first pre-
scription for NMDA receptor antagonists occurred on
16th December 2002, so the analysis of this drug class
started on 1st January 2003. For each patient, we used
the month and year of diagnosis (Table 3) and first pre-
scription. For each month, we calculated the following:
(A) the number of patients receiving their first prescrip-
tion in that month and (B) the number of patients with
a diagnosis who had not received treatment before the
first of the month. Dividing A by B provided the propor-
tion of patients with diagnoses who received their first
Fig. 1 Bar graph illustrating the number of patients diagnosed with dementia, by diagnosis type. The data presented are restricted to patients
who received a diagnosis prior to 1st January 2016 and are from an English practice with a last data collection date in 2016 to reflect the main
analysis. Definitions for each of the diagnoses are presented in Table 3.
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prescription for the treatment of interest each month.
We also calculated the SE of this proportion [26]. Trend
analysis using joinpoint models was then conducted.
The optimal number of joinpoints, as determined by the
software and up to a maximum number of 2, was used
to select the model. We refer to the period between two
joinpoints as a ‘segment’ and number them chronologic-
ally. Our model assumes that the rate of prescription
‘changes at a constant percentage of the rate of the pre-
vious year’ [27] and so is determined by the following
equation: lny = xb. This allows us to consider the
monthly percent change. The trend over the entire study
period is summarized using the average monthly percent
change. This is calculated as the average of the monthly
percent changes, weighted by segment length [28]. All
analysis was conducted using Joinpoint Regression
Program (version 4.3.1.0; National Cancer Institute,
Bethesda, MD, USA) and Stata (version 14.1; Stata-
Corp, College Station, TX, USA) software [29, 30].
The model specifications for the joinpoint analyses
are the software’s default with dependent variable type
set to ‘proportion’ and the maximum number of join
points set to 2. The Stata code used in this analysis is
available from GitHub (https://github.com/venexia/
DementiaDrugsCPRD) [31].
News search
Several of the national guidelines and initiatives
considered in this study may have increased aware-
ness of dementia, including Alzheimer’s disease. To
investigate this, we downloaded the Google Trends
(https://trends.google.com/trends/) data for news
searches in England for the disease term ‘Alzheimer’s
disease’ from 1st January 2008 up to 1st January
2016 [32]. Unfortunately, data were not recorded
prior to 2008, so we cannot comment on the effect
media coverage may have had on trend changes iden-
tified before this point in time. As with the main
analysis, data were processed and plotted using Stata
(version 14.1; StataCorp, College Station, TX, USA),
and the code is available from GitHub (https://
github.com/venexia/DementiaDrugsCPRD) [29, 30].
Results
Trend analysis for AChE inhibitors
The proportion of patients with probable Alzheimer’s
disease receiving their first prescription for an AChE in-
hibitor increased throughout the study period (Fig. 2).
This is reflected in the average monthly percent change,
which was 6.0 (95% CI, − 6.4 to 19.9) for the period from
June 1997 to December 2015. For much of the study
period, the trend was for an increasing proportion of pa-
tients to receive their first prescription for an AChE in-
hibitor with a monthly percent change of 5.4 (95% CI,
4.2 to 6.7). In October 2012 (95% CI; September 2011 to
April 2013; p = 0.816), the prescription rate surged with
a monthly percent change of 67.2 (95% CI, − 96.6 to
8179.8). Less than 1 year later, in May 2013 (95% CI;
November 2012 to April 2014; p = 0.789), the trend re-
versed so that prescription rates were falling. In the
months that followed, the monthly percent change had a
value of − 1.6 (95% CI, − 10.4 to 8.1), falling below zero
for the first time since the launch of these drugs.
Trend analysis for NMDA receptor antagonists
Figure 3 presents the equivalent analysis for the NMDA
receptor antagonist memantine. Memantine became
available in January 2003 and was prescribed much less
often than the other drugs, despite similar numbers of
eligible patients. This is partly related to the indication
of these drugs. Memantine is generally recommended
for more advanced disease than the AChE inhibitors and
is often added to a prescription of AChE inhibitors
following progression of the disease. Despite this, as ob-
served for the AChE inhibitors, the proportion of pa-
tients with probable Alzheimer’s disease receiving their
first prescription for an NMDA receptor antagonist
increased on average throughout the study period. The
average monthly percent change for the period from
January 2003 to December 2015 was 15.4 (95% CI, −
77.1 to 480.9), though the 95% CI around this estimate
is large. The initial trend for prescribing of this drug
showed a reduced number of prescriptions in the time
that followed the launch with a monthly percent change
of − 5.3 (95% CI, − 12.6 to 2.6). This changed around
Table 3 Diagnosis definitions used in the study, presented with the number of patients
Diagnosis Definition Patients
Probable AD Patients with one or more codes on the list ‘probable AD’. Patients may also have codes on the lists
‘possible AD’, ‘donepezil’, ‘rivastigmine’, ‘galantamine’ and ‘memantine’.
10,651
Possible AD Patients with one or more codes on the list ‘possible AD’. Patients may also have codes on the lists
‘donepezil’, ‘rivastigmine’, ‘galantamine’ and ‘memantine’.
12,167
Non-AD and mixed dementias Patients with one or more codes on any of the following lists: ‘probable AD’, ‘possible AD’, ‘other
dementia’, ‘vascular dementia’, ‘non-specific dementia’, ‘donepezil’, ‘rivastigmine’, ‘galantamine’ and
‘memantine’, who do not meet the above criteria.
17,384
AD Alzheimer’s disease
The data presented are restricted to patients who received a diagnosis prior to 1st January 2016 and are from an English practice with a last data collection date
in 2016 to reflect the main analysis. The total number of patients with ‘any dementia’ is 40,202
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Fig. 2 Indicative graph of acetylcholinesterase (AChE) inhibitor prescriptions in patients with probable Alzheimer’s disease. This graph shows the
proportion of patients with probable Alzheimer’s disease receiving their first prescription for an AChE inhibitor each month from June 1997 to
December 2015. The fixed lines indicate events with the potential to affect prescription rates during the study period. The joinpoints, monthly
percent change (MPC) for each segment, and the average monthly percent change (AMPC) for the entire study period are also presented
Fig. 3 Indicative graph of N-methyl-D-aspartate (NMDA) receptor antagonist prescriptions in patients with probable Alzheimer’s disease. This
graph shows the proportion of patients with probable Alzheimer’s disease receiving their first prescription for an NMDA receptor antagonist each
month from January 2003 to December 2015. The fixed lines indicate events with the potential to affect prescription rates during the study
period. The joinpoints, the monthly percent change (MPC) for each segment, and the average monthly percent change (AMPC) for the study
period are also presented
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March 2011 (95% CI, August 2010 to April 2011, p =
0.892) to a very strong trend for increased prescribing.
From the second trend change in June 2011 (95% CI,
April 2011 to November 2011, p = 0.896) until the end
of the study in December 2015, this trend reduced to a
monthly percent change of 20.7 (95% CI, 15.3 to 26.4).
This indicates a continuing increase in the prescriptions
for NMDA receptor antagonists in recent years, albeit
substantially reduced from the rise observed between
March and June 2011. The complete output for both this
analysis and that relating to AChE inhibitors is provided
in Additional file 3.
Sensitivity analyses
We repeated the main analysis, which considers the
diagnosis ‘probable Alzheimer’s disease’, with relaxed
diagnosis definitions to test the sensitivity of our results.
We did this in two ways: (1) introducing codes that rep-
resented what may be lesser degrees of confidence in the
accuracy of Alzheimer’s disease diagnosis (termed any
Alzheimer’s disease) and (2) introducing codes capturing
other types of dementia (termed any dementia). The re-
sults of these further analyses are provided in Additional
file 3, and a summary of all results can be found in
Table 4. For NMDA receptor antagonists, the joinpoint
analysis is consistent regardless of the diagnosis defin-
ition used. However, for AChE inhibitors, the joinpoint
analysis varies according to the diagnosis definition used,
though the two sensitivity analyses are reasonably con-
sistent with each other.
News search
Figure 4 presents the Google Trends data for news
searches in England for the disease term ‘Alzheimer’s
disease’ each month from January 2008 to December
2015, inclusive. There were no strong trends in the
interest for the search term, with values indicating both
low and high interest occurring throughout the period
studied. Months with insufficient data, indicating little
interest in the search term, became less common over
the period studied, with the most recent occurring in
August 2015. Interest peaked in September 2012 and
was also high in January 2011 (88%), January 2010 (82%)
and April 2008 (81%).
Discussion
The first trend change for the proportion of patients
with probable Alzheimer’s disease receiving their first
prescription for an AChE inhibitor occurred in October
2012 (95% CI, September 2011 to April 2013, p = 0.816).
At this time, a long-term steadily increasing trend be-
came a very strong increasing trend. This surge could be
related to two factors. Firstly, the patents expired on the
three drugs in this class in 2012—galantamine in January
2012, donepezil in February 2012 and rivastigmine in
July 2012. Secondly, the Prime Minister’s Dementia
Challenge launched in May 2012. It is likely that the re-
duction in cost of these drugs, which resulted from their
patents expiring, in combination with increased aware-
ness of dementia due to the Prime Minister’s Dementia
Challenge, led to this substantial change in prescription
rates we observed. In addition to these factors, a large
amount of literature concerning AChE inhibitors had
been published ahead of the revisions to the NICE guid-
ance in 2011. Although this is unlikely to have caused
the sharp surge that we observed, it could have contrib-
uted to the long-term steadily increasing trend observed
prior to this change. A systematic review which covers
the literature through November 2014 (i.e., after all join
points identified in our analysis but 13 months before
the end of our study) summarizes the literature available
at that time [33]. It shows that several studies published
Table 4 Comparison of the sample sizes and joinpoint estimates, presented with 95% confidence intervals, for all analyses
Probable AD Any AD Any dementia
Source Main analysis Additional file 3 Additional file 3
Diagnoses Probable AD Probable AD
Possible AD
Probable AD
Possible AD
Non-AD and mixed dementias
AChE inhibitors Eligible: 10,456
Treated: 5019
Joinpoint 1: Oct 2012
(Sep 2011–Apr 2013)
Joinpoint 2: May 2013
(Nov 2012–Apr 2014)
Eligible: 21,342
Treated: 6449
Joinpoint 1: Jun 1999
(Apr 1998–Dec 2000)
Joinpoint 2: Jun 2001
(Sep 2000–Mar 2002)
Eligible: 38,650
Treated: 9896
Joinpoint 1: Aug 2000
(Jun 1998–Nov 2000)
Joinpoint 2: Jan 2001
(Sep 2000–Nov 2001)
NMDA receptor antagonists Eligible: 9964
Treated: 1052
Joinpoint 1: Mar 2011
(Aug 2010–Apr 2011)
Joinpoint 2: Jun 2011
(Apr 2011–Nov 2011)
Eligible: 18,930
Treated: 1309
Joinpoint 1: Sep 2010
(Dec 2009–Apr 2011)
Joinpoint 2: Nov 2011
(Apr 2011–Mar 2012)
Eligible: 35,625
Treated: 1961
Joinpoint 1: Aug 2010
(Nov 2009–Dec 2010)
Joinpoint 2: Nov 2011
(Aug 2011–Mar 2012)
AChE Acetylcholinesterase, AD Alzheimer’s disease, NMDA N-methyl-D-aspartate
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between 2003 and 2008 suggested that patients with
mild to moderate Alzheimer’s disease could benefit from
AChE inhibitors with estimated ‘improvements on the
order of 1.5 MMSE (30-point scale)’. We therefore can-
not rule out a potential effect of the literature on pre-
scribing, even though the authors of the review
questioned whether such an improvement was clinically
meaningful when all the evidence was presented to-
gether. Further to the support from the literature, the
Google Trends data for news searches in England also
suggested increased awareness around the time of this
trend change. The interest for the search term ‘Alzhei-
mer’s disease’ was at its maximum in September 2012
(based on the data available from January 2008 to De-
cember 2015, inclusive), which could indicate interest
among the public.
The second trend change in the AChE inhibitor ana-
lysis occurred in May 2013 (95% CI, November 2012 to
April 2014, p = 0.789), less than 1 year after the initial
change for this drug class and with overlapping 95% CIs.
This change signals the end of the surge in prescribing
and the start of a decreasing trend in prescriptions. This
is not unexpected, because patent expiry may have led
to a form of ‘catch-up prescribing’ whereby people who
were previously denied access to the drug were granted
access at this time owing to its newly reduced cost. This
would result in the apparent decreasing trend once
‘catch-up prescribing’ was complete, which is suggested
by the trend analysis but is not as clear when considering
the raw data points. These results differ from the sensitiv-
ity analyses that considered relaxed diagnosis definitions,
though the ‘any Alzheimer’s disease’ and ‘any dementia’
analyses were in line with each other. This suggests that
prescribing for patients with probable Alzheimer’s disease
was more consistent, as one might expect, across the
study than for other groups. This could indicate that pa-
tients with dementias other than probable Alzheimer’s dis-
ease (i.e., with unlicensed indications) were receiving these
drugs and that their prescriptions were subject to change
over the period studied. Further to this, large increases in
prescriptions are observed as the diagnosis definition is re-
laxed. This could provide further evidence for the possible
unlicensed use of this drug class. The literature at that
time also reflects ongoing discussion concerning the bene-
fit of these drugs for indications other than Alzheimer’s
disease. For example, a 2012 review by Rodda and Carter
discusses their use in vascular dementia, dementia with
Lewy bodies and Parkinson’s disease dementia [34]. Alter-
natively, it could be attributed to the fluctuating course of
symptoms that some people with dementia experience or
increased recognition of mixed diagnoses where there is
evidence of Alzheimer’s disease in addition to other forms
of dementia, both of which might lead to treatment
changes.
Fig. 4 Google Trends data for news searches in England for the disease term ‘Alzheimer’s disease’. This graph shows the interest in the disease
term ‘Alzheimer’s disease’ each month from January 2008 to December 2015, inclusive. Interest is given as a percentage scaled against peak
popularity, which is represented as a value of 100% and occurred for the downloaded data in September 2012. Values of zero indicate insufficient
data for that month
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The trend changes in the NMDA receptor antagonist
analysis occurred in March 2011 (95% CI, August 2010
to April 2011, p = 0.891) and June 2011 (95% CI, April
2011 to November 2011, p = 0.896). Notably, the 95% CI
for the first trend change ends in April 2011, which is
when the 95% CI for the second trend change begins.
This suggests that the trend changes may be related.
The first of these trend changes marks the start of a
strong increasing trend that changes to a steadily in-
creasing trend following the second trend change. In
March 2011 NICE introduced guidelines that recom-
mended the prescription of memantine for patients with
moderate to severe Alzheimer’s disease or for those
people who could not tolerate AChE inhibitors. This
replaced existing guidelines that restricted access to
memantine to patients participating in clinical trials. It
would therefore seem that these trend changes relate to
the transition between the existing guidelines and those
introduced in March 2011. In addition, we observed the
second highest peak in interest (88% of maximum inter-
est) for the disease term ‘Alzheimer’s disease’ in the Goo-
gle Trends data for news searches in England in January
2011. In this month, the ‘Final Appraisal Determination
on Donepezil, galantamine, rivastigmine and memantine
for the treatment of Alzheimer’s disease’ was released.
NICE defined this document as ‘the appraisal commit-
tee’s final draft guidance about using a treatment or
group of treatments in the NHS’, which becomes
guidance if not appealed [35]. The increase in news
searches around this time, and its alignment with the re-
lease of the final draft guidance, supports the idea of a
transition in prescribing practice due to the NICE guid-
ance. Finally, the evidence concerning the use of mem-
antine is summarized in a technology appraisal
conducted by NICE in 2011 to support their guidance
[11]. We cannot disentangle the role that this informa-
tion from several studies published prior to the trend
change might have played in changes to prescribing.
Interestingly, neither of the trend changes in the
NMDA receptor antagonist analysis aligns with those
observed for the AChE inhibitors. This suggests that the
NICE guidelines, which were implemented at the same
time for both drug classes, may not have been as effect-
ive for AChE inhibitors. This is likely due to the fact that
these drugs were available outside of clinical trials prior
to the restrictive guidelines recommended in 2006. The
sensitivity analyses conducted for the NMDA receptor
antagonists were consistent with these results, regardless
of the diagnosis definition used. The first of the join-
points for all NMDA receptor antagonist analyses oc-
curred in the 7-month period between August 2010 and
March 2011, and the second occurred in the 6-month
period between June 2011 and November 2011. This
high level of consistency across diagnosis definitions
indicates a clear pattern in prescribing, suggestive of a
distinct change in practice. This provides additional sup-
port for our inferences concerning the impact of the
2011 NICE guidance on the NMDA receptor antagonist
drug class.
Strengths and limitations
The key strength of this study is the large sample of pri-
mary care data with prescribing information, provided
by the CPRD. The CPRD is ‘broadly representative of
the UK general population’ and was generally compar-
able to the last census in 2011 for age, sex and ethni-
city despite young people and smaller practices tending
to be slightly underrepresented [36, 37]. Our data extract
contains 40,202 patients diagnosed with dementia in
England up to 1st January 2016 (note that data are re-
stricted to practices with a last data collection date in
2016), including 10,651 with probable Alzheimer’s dis-
ease and a further 12,167 with possible Alzheimer’s dis-
ease. A further strength of our study is the long
follow-up of patients that allowed us to consider patients
who did not receive immediate treatment. This is im-
portant because pharmacological interventions for
Alzheimer’s disease have historically considered severity
as part of the prescribing decision, so there is likely to
be a treatment delay after initial diagnosis for those pre-
senting with mild disease.
The main limitation of our study is the likelihood of
missed diagnoses. This is demonstrated within our data-
set, because there were 1231 patients receiving one of
the treatments of interest who did not have any form of
recorded dementia diagnosis. Missed diagnoses are likely
to be due to (1) outdated or non-specific diagnoses (i.e.,
type of dementia is not updated once established), (2)
diagnoses received outside of primary care (i.e., from a
specialist service) and (3) unrecorded diagnoses in pri-
mary care (i.e., a diagnosis is given but not added to a
record). Missed diagnoses have been explored in sensi-
tivity analyses by testing the sensitivity and specificity of
our diagnosis definitions (Additional file 2) and by relax-
ing the diagnosis definition from ‘probable Alzheimer’s
disease’ to include other less certain codes for the
disease and other types of dementia (Additional file 3).
Neither of these sensitivity analyses provided any cause
for concern. A final limitation of this study is the diffi-
culty in determining the lag time between an event and
a trend change to assess the impact of the event. To
allow for this, we have focused on events that are con-
sidered to be of greatest impact—for example, changes
at a national level—and so we expect any effect associ-
ated with them to be evident if present. However, this
prevents us from covering all the factors that may influ-
ence prescriptions for drugs for dementia during the
study period; for example, we cannot comment on all
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papers concerning these drugs published during this
time.
Conclusions
Analysis of both drug classes indicates that inclusion of
dementia in QOF had no effect on prescribing trends
and the other factors had mixed effects. NICE guidance
on the prescribing of drugs for dementia aligned with
trend changes for NMDA receptor antagonists but not
AChE inhibitors. The guidance that had the noticeable
effect was released in March 2011 and allowed the
NMDA receptor antagonist memantine to be used out-
side of clinical trials. All other guidance for both this
drug and AChE inhibitors, including that which recom-
mended restricting access, did not align with trend
changes. Government dementia strategies also appear to
have had mixed results, with the Prime Minister’s
Dementia Challenge (launched May 2012) being the only
strategy to align with a trend change. Although this
strategy is likely to have increased awareness of demen-
tia around the time of the October 2012 trend change
for AChE inhibitors, we believe that the more likely
cause of this change is the patent expiry of the drugs in
this class. This will have reduced the cost of these drugs
and potentially led to a surge in prescribing, such as that
observed in our trend analysis. The events considered
here highlight the many factors that may have influenced
prescribing rates and the challenges in assessing the
impact of a given event. Overall it would seem that the
proportion of patients receiving prescriptions increased
over the period studied, regardless of changing
guidelines and other initiatives. Furthermore, given the
increase in diagnoses of dementia and, more specifically,
Alzheimer’s disease reported in the CPRD (Fig. 1), the
absolute number of prescriptions has increased consider-
ably over the period studied.
To our knowledge, there are two other studies that
have considered prescribing trends, and these were fo-
cused mainly on the impact of the National Dementia
Strategy [2, 3]. Our study extends the findings of these
previous studies because it considers trends since the
launch of these drugs and implements a joinpoint model
as a hypothesis-free approach for the factors affecting
prescribing. We have observed that prescription rates in
England do not always respond to factors such as regula-
tory guidance, recommendations or patent expiry, and
when they do, not necessarily in a predictable way. This
suggests that communication with clinicians may need
to be improved to use drugs for dementia more
cost-effectively. In addition to this, the present study
provides insight into the factors that may have influ-
enced prescription rates of drugs for dementia in Eng-
land since their launch in 1997. This is essential for
accurate assessment of the effectiveness of these
treatments and to adjust for them in other forms of
analyses, particularly as factors that may modify the
rates of disease progression. This study may also help
to inform the handling of regulatory guidance and
recommendations concerning drugs for dementia in
the future.
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